Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 3/20 | 0.47 |
| ▸ | WNT3A | P56704 | 3/20 | 0.47 |
| ▸ | PDE2A | O00408 | 10/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29085951 | 1.00 | CTNNB1 (0.47) | CTNNB1WNT3APDE2AHDAC4OGA | |
| SCHEMBL31373869 | 0.77 | PDE2A (0.58) | CTNNB1WNT3APDE2AACACB | |
| SCHEMBL3314656 | 0.73 | NPC1 (0.46) | — | |
| SCHEMBL11167223 | 0.72 | PDE2A (0.47) | CTNNB1WNT3APDE2AOGAACACB | |
| SCHEMBL18237188 | 0.71 | PDE2A (0.61) | CTNNB1WNT3APDE2AOGAACACB | |
| SCHEMBL17541572 | 0.71 | PDE2A (0.44) | CTNNB1WNT3APDE2AOGAACACB | |
| SCHEMBL26938923 | 0.71 | PDE2A (0.44) | CTNNB1WNT3APDE2AOGAACACB | |
| SCHEMBL26923716 | 0.71 | PDE2A (0.44) | CTNNB1WNT3APDE2AOGAACACB | |
| SCHEMBL30687097 | 0.71 | PDE2A (0.44) | CTNNB1WNT3APDE2AOGAACACB | |
| SCHEMBL15943248 | 0.71 | PDE2A (0.44) | CTNNB1WNT3APDE2AOGAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444506-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-108892661-B | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | CTNNB1 3511/4885WNT3A 2586/4885PDE2A 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.